Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine

Next Previous
X
Search
Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 30 May 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ubrogepant (Primary)
  • Indications Migraine; Migraine with aura; Migraine without aura
  • Focus Registrational; Therapeutic Use
  • Acronyms ACHIEVE I
  • Sponsors Allergan

    • Most Recent Events

    • 26 Apr 2022 Results of pooled analysis from ACHIEVE I and ACHIEVE II trials demonstrating therapeutic benefit at 1-Hour post-dose presented at the 74th Annual Meeting of the American Academy of Neurology 2022
    • 07 Dec 2021 Results of post hoc pooled analysis, assessing efficacy endpoints from ACHIEVE I and ACHIEVE II (n=2247) and safety outcomes from NCT02873221 (n=813); published in the Advances in Therapy
    • 10 Jun 2021 Data from this study and ACHIEVE II trial has been used to review the pharmacology, efficacy and safety of ubrogepant as an abortive migraine treatment published in the Annals of Pharmacotherapy

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top